Important Notice from CHUGAI PHARMACEUTICAL
ABOUT
We get to the future ahead of the disease.
Chugai is a research and development-oriented pharmaceutical company with unique technology and science as its strengths. In collaboration with Roche, we are committed to continuously generating innovation with the aim of continuously providing patients with innovative drugs and services.
-
*1 Copyright © 2026 IQVIA. Calculated based on JPM 2025. Reprinted with permission. The scope of the market is defined by Chugai.
-
*2 A system introduced in July 2012 by the U.S. Food and Drug Administration aimed at expediting the development and review of drugs for the treatment of severe or life-threatening diseases or symptoms.
-
INNOVATION
We want to eradicate diseases that have no treatments.
That is what an innovator should be.
The three key drivers driving Chugai's growth are RED*Research and Early Development Shift, DX,
and open innovation.
We will shift our resources to discovery
research and early clinical development, which are the source of
our value creation, apply digital technology to create innovative
new drugs and increase efficiency in the value chain, and actively
collaborate with external partners.
* Research and Early Development
The purpose of innovation, R&D efforts, and results
SUSTAINABILITY
Putting sustainability at the heart of our business
Creating shared value with Society and developing together
Stories
Creating Continuous Innovation.
The Story of Our Challenges
UPDATE
Latest Information
-
Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai) have been awarded the Lasker-DeBakey Clinical Medical Research Award, one of the world’s most prestigious scientific honors.
-
Announcement of Partnership with the Japan Basketball Association (JBA)
-
Chugai Joins Bakar Bio Labs Industry Affiliate Program at UC Berkeley
-
Transcript (including Q&A) for Conference on FY2026.12 Q2 Financial Results
-
Conference on FY 2026.12 Q2 Financial Results
-
Financial Results for Second Quarter of Fiscal Year 2026 (Jan-Jun 2026)
-
Script (including Q&A) for Conference on FY2026.12 Q1 Financial Results
-
Financial Results for First Quarter of Fiscal Year 2026 (Jan-Mar 2026)
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
-
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Lorlatinib for ALK Fusion Gene-Positive Non-Small Cell Lung Cancer
-
Roche Announces Phase III CELESTIMO Study Results for Lunsumio in Relapsed or Refractory Follicular Lymphoma
-
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Tovorafenib for BRAF V600 Alterations and BRAF Fusion Gene-Positive Glioma
-
Personnel Changes
-
Roche Announces U.S. FDA Grants Priority Review for Enspryng for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)